Esperion Therapeutics Inc 2024年度报告

We remain grateful to our loyal shareholders who continueto support our mission as we evolve Esperion into a leadingglobal biopharmaceutical company delivering innovative newmedicines that help patients reach their goals today, tomorrow,and into the future. We entered 2025 following a watershed year in 2024 thatwas marked by increased revenue, global expansion and asignificantly strengthened financial foundation! During 2024 we made significant progress launching theexpanded labels we received from the U.S. Food and DrugAdministration (FDA) for NEXLETOL® (bempedoic acid)and NEXLIZET® (bempedoic acid and ezetimibe), which arenow the only non-statins indicated for cardiovascular riskreduction in both primary and secondary prevention patients. 2025 will be a new era of Esperion as we increase adoption ofNEXLETOL and NEXLIZET in the U.S., expand our commercialreach globally and introduce exciting new clinical developmentopportunities. Since launching the new indications, we have made importantadvances with contracted payers and our innovative outreachto healthcare providers has allowed us to post double-digitsequential quarterly prescription growth. Collectively, theseinitiatives strengthen our foundation for future growth as wecontinue to bring our life-saving preventative therapies to themore than 70 million patients in the U.S. alone who could beeligible for our innovative medicines. Sheldon KoenigPresident & ChiefExecutive Officer Throughout 2024, we made great strides strengthening ourbalance sheet. In June 2024, we monetized our royalty onDaiichi Sankyo Europe’s (DSE) net sales of bempedoic acidproducts in Europe for $304.7 million and used the proceedsto terminate an existing revenue interest facility. In December 2024, we supported the repayment of a portionof our existing $265 million convertible debt facility withtransactions that included a $150 million senior secured termloan facility led by prominent healthcare investors and issued$100 million in new Convertible Notes. Together, these transformational transactions provide us withincreased operational and financial flexibility to build and expandour business globally, and the company has never had a moresolid financial foundation to support it. Having successfully brought the first ACLY inhibitors tomarket, NEXLETOL and NEXLIZET, our scientific team is makingmeaningful progress advancing the investigation of ACLYbiology to treat additional indications of unmet medical need.Leveraging our leading-edge discovery technologyand data science approaches, we aim to reveal new therapeuticopportunities optimized to address multiple life-threateningdiseases in 2025. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549FORM10-K Commission file number:001-35986 Securities registered pursuant to Section 12(g) of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes☐No☒ Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” inRule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal controlover financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued itsaudit report.☒If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐Indicate by check mark whether